Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
Y-mAbs Therapeutics (Nasdaq: YMAB) has appointed Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. This appointment comes as part of the company's strategy to expand the commercial potential of DANYELZA beyond pediatric oncology. Gentilcore brings over 20 years of pharmaceutical industry experience, previously serving as CEO of ARTMS, Inc. and founding Implerem, His background includes leadership roles at Jubilant Radiopharma, General Electric Healthcare Division, and Pfizer Pharmaceuticals.
The appointment coincides with the departure of Chief Commercial Officer Sue Smith, who led the U.S. Commercial team and DANYELZA relaunch. The company believes Gentilcore's extensive experience in pharmaceutical commercialization and global operations will be important for DANYELZA's growth strategy.
Y-mAbs Therapeutics (Nasdaq: YMAB) ha nominato Doug Gentilcore come Vicepresidente Senior, Capo dell'Unità Business DANYELZA. Questa nomina fa parte della strategia dell'azienda per espandere il potenziale commerciale di DANYELZA oltre l'oncologia pediatrica. Gentilcore porta con sé oltre 20 anni di esperienza nell'industria farmaceutica, avendo precedentemente ricoperto il ruolo di CEO di ARTMS, Inc. e fondato Implerem. Il suo background include ruoli di leadership presso Jubilant Radiopharma, General Electric Healthcare Division e Pfizer Pharmaceuticals.
La nomina coincide con la partenza del Chief Commercial Officer Sue Smith, che ha guidato il team commerciale statunitense e il rilancio di DANYELZA. L'azienda ritiene che l'ampia esperienza di Gentilcore nella commercializzazione farmaceutica e nelle operazioni globali sarà fondamentale per la strategia di crescita di DANYELZA.
Y-mAbs Therapeutics (Nasdaq: YMAB) ha nombrado a Doug Gentilcore como Vicepresidente Senior, Jefe de la Unidad de Negocios DANYELZA. Este nombramiento forma parte de la estrategia de la empresa para expandir el potencial comercial de DANYELZA más allá de la oncología pediátrica. Gentilcore aporta más de 20 años de experiencia en la industria farmacéutica, habiendo sido anteriormente CEO de ARTMS, Inc. y fundador de Implerem. Su trayectoria incluye roles de liderazgo en Jubilant Radiopharma, la División de Salud de General Electric, y Pfizer Pharmaceuticals.
El nombramiento coincide con la salida de la Directora Comercial Sue Smith, quien dirigió el equipo comercial de EE. UU. y el relanzamiento de DANYELZA. La empresa cree que la amplia experiencia de Gentilcore en comercialización farmacéutica y operaciones globales será importante para la estrategia de crecimiento de DANYELZA.
Y-mAbs Therapeutics (Nasdaq: YMAB)가 Doug Gentilcore를 수석 부사장 겸 DANYELZA 사업부 책임자로 임명했습니다. 이 임명은 DANYELZA의 상업적 잠재력을 소아 종양학을 넘어서 확장하려는 회사의 전략의 일환입니다. Gentilcore는 ARTMS, Inc.의 CEO로 재직했던 경험을 포함하여, 20년 이상의 제약 산업 경험을 가지고 있습니다. 그의 경력에는 Jubilant Radiopharma, General Electric Healthcare Division, 및 Pfizer Pharmaceuticals에서의 리더십 역할이 포함되어 있습니다.
이 임명은 미국 상업 팀과 DANYELZA의 재출시를 이끌었던 상업 책임자 Sue Smith의 퇴사와 동시에 이루어졌습니다. 회사는 Gentilcore의 제약 상업화 및 글로벌 운영에 대한 광범위한 경험이 DANYELZA의 성장 전략에 중요할 것이라고 믿고 있습니다.
Y-mAbs Therapeutics (Nasdaq: YMAB) a nommé Doug Gentilcore au poste de Vice-président senior, responsable de l'unité commerciale DANYELZA. Cette nomination s'inscrit dans la stratégie de l'entreprise visant à élargir le potentiel commercial de DANYELZA au-delà de l'oncologie pédiatrique. Gentilcore possède plus de 20 ans d'expérience dans l'industrie pharmaceutique, ayant précédemment été PDG d'ARTMS, Inc. et fondateur d'Implerem. Son parcours comprend des postes de direction chez Jubilant Radiopharma, la division santé de General Electric et Pfizer Pharmaceuticals.
La nomination coïncide avec le départ de la directrice commerciale Sue Smith, qui a dirigé l'équipe commerciale américaine et le relancement de DANYELZA. L'entreprise estime que l'expérience approfondie de Gentilcore en matière de commercialisation pharmaceutique et d'opérations mondiales sera importante pour la stratégie de croissance de DANYELZA.
Y-mAbs Therapeutics (Nasdaq: YMAB) hat Doug Gentilcore zum Senior Vice President und Leiter der DANYELZA-Geschäftseinheit ernannt. Diese Ernennung ist Teil der Strategie des Unternehmens, das kommerzielle Potenzial von DANYELZA über die pädiatrische Onkologie hinaus zu erweitern. Gentilcore bringt über 20 Jahre Erfahrung in der Pharmabranche mit, nachdem er zuvor als CEO von ARTMS, Inc. tätig war und Implerem gegründet hat. Zu seinem Hintergrund gehören Führungspositionen bei Jubilant Radiopharma, der General Electric Healthcare Division und Pfizer Pharmaceuticals.
Die Ernennung fällt mit dem Ausscheiden der Chief Commercial Officer Sue Smith zusammen, die das US-Vertriebsteam und das Wiederlaunch von DANYELZA leitete. Das Unternehmen ist der Ansicht, dass Gentilcores umfangreiche Erfahrung in der pharmazeutischen Vermarktung und globalen Aktivitäten wichtig für die Wachstumsstrategie von DANYELZA sein wird.
- Strategic hire with over 20 years of pharmaceutical commercialization experience
- Potential expansion of DANYELZA beyond current pediatric oncology market
- Departure of Chief Commercial Officer during commercial expansion phase
- Leadership transition may cause temporary disruption in commercial operations
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit.
“I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,” said Michael Rossi, President and Chief Executive Officer. “We believe Doug’s extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our continued commercial expansion and growth to unlocking the full potential value of DANYELZA beyond pediatric oncology.”
Mr. Gentilcore brings over two decades of strategic leadership experience in the pharmaceutical industry. Prior to joining Y-mAbs, he served as Chief Commercial Officer and then Chief Executive Officer of ARTMS, Inc., a global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. Upon the company’s acquisition by Telix Pharmaceuticals, Mr. Gentilcore returned to a full-time role at Implerem, LLC, a commercial pharmaceutical consulting firm he founded in 2019. Prior to ARTMS, Mr. Gentilcore was Vice President of Global Sales and Business Operations at Jubilant Radiopharma, where he led all commercial operations for the company, including the go-to-market strategy for Jubilant DraxImage Radiopharma. Earlier, Mr. Gentilcore held sales roles of increasing responsibility at General Electric’s Healthcare Division in Medical Diagnostics and was a regional commercial leader at Pfizer Pharmaceuticals. He received a B.A. in Business Economics from Randolph-Macon College.
Sue Smith, Chief Commercial Officer, will be departing the organization. Mr. Rossi commented, “On behalf of the Board of Directors and the entire Y-mAbs teams, I want to thank Sue for her commitment in leading our U.S. Commercial team and on the relaunch of DANYELZA. Sue has been a valued member of our leadership team, and we wish her all the best in her future endeavors.”
About DANYELZA® (naxitamab-gqgk)
DANYELZA® (naxitamab-gqgk) is indicated, in combination with granulocyte-macrophage colony-stimulating factor ("GM-CSF"), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication was approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory trial. DANYELZA® includes a Boxed Warning for serious infusion-related reactions, such as cardiac arrest and anaphylaxis, and neurotoxicity, such as severe neuropathic pain and transverse myelitis. See full Prescribing Information for complete Boxed Warning and other important safety information.
DANYELZA is currently not approved for the treatment of osteosarcoma in any jurisdiction.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s business is subject to risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SADA®, SADA PRIT®, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
Who is the new Head of DANYELZA Business Unit at Y-mAbs (YMAB)?
What is Y-mAbs' (YMAB) strategy for DANYELZA expansion?
What is Doug Gentilcore's background before joining Y-mAbs (YMAB)?
Why is Sue Smith leaving Y-mAbs (YMAB)?
